Top

Published in:

01-08-2009 | Case Report

Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics

Authors: Gerhard J. Molderings, Gerold Solleder, Ulrich W. Kolck, Jürgen Homann, Detlev Schröder, Ivar von Kügelgen, Roland Vorreuther

Published in: Urolithiasis | Issue 4/2009

Abstract

Urolithiasis is expected to cause a considerable complication in patients with systemic mastocytosis. The aim of the present report is to demonstrate that due to pathological activation and irritability of mast cells, special features in the diagnostic investigation and therapy of urolithiasis have to be considered in patients with systemic mastocytosis. The clinical presentation, diagnostic investigation and therapeutic procedure of urolithiasis in a patient with systemic mastocytosis are described. Urolithiasis may be a significant complication of systemic mastocytosis. Non-contrast CT is the main tool for diagnosing urolithiasis after a detailed history and clinical exam. Patients with systemic mastocytosis should receive a premedication composed of a glucocorticoid and H₁- and H₂-histamine receptor antagonists. An increased vulnerability of mucosal tissues is expected in patients with systemic mastocytosis that may limit the options of operative and postoperative therapy. Opioids should be used cautiously for analgesia in patients with systemic mastocytosis.

Valent P, Akin C, Escribano L et al (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37:435–453. doi:10.1111/j.1365-2362.2007.01807.x PubMedCrossRef

Ruëff F, Dugas-Breit S, Bauer C et al (2006) Mastocytosis—clinical picture and diagnosis. Dtsch Med Wochenschr 131:1616–1621. doi:10.1055/s-2006-947809 PubMedCrossRef

Molderings GJ, Kolck UW, Scheurlen C et al (2007) Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol 42:1045–1053. doi:10.1080/00365520701245744 PubMedCrossRef

Alfter K, von Kügelgen I, Haenisch B et al (2008) New aspects of liver abnormalities as part of the systemic mast cell activation syndrome. Liver Int. doi:10.1111/j.1478-3231.2008.01839.x

Manion SP, Wheeler JS (1996) Systemic mastocytosis: a possible aetiology of nephrolithiasis. Br J Urol 78:643–644PubMed

Lanternier F, Cohen-Akenine A, Palmerini F et al (2008) Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS ONE 3:e1906PubMedCrossRef

Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36:32–36. doi:10.1016/j.semarthrit.2006.03.004 PubMedCrossRef

Caudarella R, Vescini F, Buffa A et al (2004) Osteoporosis and urolithiasis. Urol Int 72(Suppl 1):17–19. doi:10.1159/000076585 PubMedCrossRef

Díaz-López B, Cannata-Andía JB (2006) Supplementation of vitamin D and calcium: advantages and risks. Nephrol Dial Transpl 21:2375–2377. doi:10.1093/ndt/gfl286 CrossRef

10.

Carter MC, Uzzaman A, Scott LM et al (2008) Pediatric mastocytosis: routine anesthetic management for a complex disease. Anesth Analg 107:422–427PubMedCrossRef

11.

Liccardi G, Lobefalo G, Di Florio E et al (2008) Strategies for the prevention of asthmatic, anaphylactic and anaphylactoid reactions during the administration of anesthetics and/or contrast media. J Investig Allergol Clin Immunol 18:1–11PubMed

12.

Fujimoto T, Nishiyama T, Hanaoka K (2005) Inhibitory effect of intravenous anesthetics on mast cell function. Anesth Analg 101:1054–1059. doi:10.1213/01.ane.0000166955.97368.80 PubMedCrossRef

13.

Sierakowski R, Finlayson B, Landes RR et al (1978) The frequency of urolithiasis in hospital discharge diagnoses in the United States. Invest Urol 15:438–441PubMed

14.

Hiatt RA, Dales LG, Friedman GD et al (1982) Frequency of urolithiasis in a prepaid medical care program. Am J Epidemiol 115:255–265PubMed

15.

Tamm EP, Silverman PM, Shuman WP (2003) Evaluation of the patient with flank pain and possible ureteral calculus. Radiology 228:319–329. doi:10.1148/radiol.2282011726 PubMedCrossRef

16.

Morse RM, Resnick MI (1991) Ureteral calculi: natural history and treatment in an era of advanced technology. J Urol 145:263–265PubMed

17.

Miller OF, Kane CJ (1999) Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol 162:688–690. doi:10.1097/00005392-199909010-00014 PubMedCrossRef

18.

Li F (2006) Pharmacologically induced histamine release: sorting out hypersensitivity reactions to opioids. Drug Ther Topics 35:13–16

19.

Sheen CH, Schleimer RP, Kulka M (2007) Codeine induces human mast cell chemokine and cytokine production: involvement of G-protein activation. Allergy 62:532–538. doi:10.1111/j.1398-9995.2007.01345.x PubMedCrossRef

Title: Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics
Authors: Gerhard J. Molderings
Gerold Solleder
Ulrich W. Kolck
Jürgen Homann
Detlev Schröder
Ivar von Kügelgen
Roland Vorreuther
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Urolithiasis / Issue 4/2009
Print ISSN: 2194-7228
Electronic ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-009-0198-0

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis

Which efficiency index for urinary stones treatment?

The effect of EDTA instillations on the rate of development of encrustation and biofilms in Foley catheters

Pain relief by extracorporeal shockwave therapy: an update on the current understanding

Genetic basis of renal cellular dysfunction and the formation of kidney stones

The influence of ureteral stent on renal pelvic pressure in vivo